Making history: Protecting vulnerable healthcare workers during COVID-19

+Practice

In print

OCCUPATIONAL HEALTH

Making history: Protecting vulnerable healthcare workers during COVID-19

13 October 2021

David McBride

Wednesday 13 October 2021, 12:10 AM

Person wearing a mask_Griffin Wooldridge on Unsplash

Deployment of healthcare staff is based on vulnerability [Image: Griffin Wooldridge on Unsplash]

Occupational health expert David McBride describes a risk assessment framework for identifying and protecting staff potentially vulnerable to COVID-19, which has been developed during an under-resourced era in occupational medicine

What has the New Zealand health service learned from the unwanted experience of COVID-19?, New Zealand needs: A response to COVID-19 that is inclusive and equitable. Occupational physicians in our hospital service, as part of the spe, Pract Green w Pale Yellow

Occupational Health

COVID-19

References

Glass B. Dr Thomas Ownsworth Garland, 1903-1993: New Zealand's pioneer in occupational medicine. Occup Med (Lond) 2003;53(8):507–11.

Bush A, Pavord I. Highlights from this issue. Thorax 2013;68(3):i.

Al-Shaqsi S, Gauld R, McBride D, et al. The state of healthcare disaster plans in New Zealand and the Sultanate of Oman: An international comparative analysis. Advances in Emergency Medicine 2014;758728.

Al-Shaqsi S, McBride D, Gauld R, et al. Are we ready? Preparedness of acute care providers for the Rugby World Cup 2011 in New Zealand. Emerg Med J 2013;30(8):611–14.

Al-Shaqsi S, Gauld R, Lovell S, et al. Challenges of the New Zealand healthcare disaster preparedness prior to the Canterbury earthquakes: a qualitative analysis. NZ Med J 2013;126(1371):9–18.

How to Treat

+How to treat

Polypharmacy

For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews

Wednesday 28 May 2025, 12:50 AM